Aardvark Stock Crashes 65% to a Record Low: The Trial Data That Erased a Rally in Hours

Aardvark stock crashed 64.8% in one day — here is what happened

Aardvark Therapeutics (NASDAQ: AARD) closed at $1.39 on Friday, October 23, 2026, down 64.8% in a single session and at a new 52-week low. The crash came hours after the company released exploratory data from its terminated Phase 3 HERO trial for ARD-101, its lead drug for hyperphagia in Prader-Willi syndrome — and just a day after the FDA lifted the full clinical hold on that same drug. It was one of the most violent one-day reversals of earnings season.

What happened

The day started in the opposite direction. After the FDA removed the clinical hold on ARD-101 on October 22, Aardvark shares were trading near $4.86 in the pre-market, well above Thursday's $3.95 close. Then, at 7:00 a.m. ET on Friday, the company published exploratory efficacy data from the previously terminated HERO trial and its open-label extension.

The release was careful — and the market read the caution, not the optimism. Aardvark said the HERO trial had randomized only 67 of its planned 90 participants before it was terminated early, so all of the efficacy data are considered exploratory. Chief Executive Officer Tien Lee, M.D., said directly that the current partial data are not sufficient to draw definitive conclusions, even while calling the results directionally consistent and saying they give the company confidence to keep developing ARD-101.

By the time the regular session opened, the pre-market gain was gone. AARD opened at $2.99, never traded back above $3.00, fell as low as $2.28 in pre-market trading, and then slid all day to close exactly at its low of $1.39. Volume told the same story: about 16.11 million shares changed hands, compared with 1.18 million the day before. The company's market value ended the day at roughly $30.4 million.

Why it's blowing up

First, the whiplash. In roughly 24 hours, Aardvark went from a regulatory win — the FDA lifting a full clinical hold that had frozen its lead program — to a reminder that clearing a hold is not the same as having convincing trial data. Investors who bought the hold-lift headline were suddenly pricing a drug whose pivotal trial had stopped early, enrolled fewer patients than planned, and produced data the company itself describes as insufficient for definitive conclusions.

Second, the timeline just got much longer. Aardvark said it plans to request a meeting with the FDA to align on the design of a new Phase 3 trial intended to support a future marketing application, and it expects to resume Prader-Willi clinical activities in 2027. That means no quick restart: a meeting, a new trial design, then a new trial. For a clinical-stage company with no product revenue, every added year is added cost and added uncertainty, which is exactly what a 65% one-day drop is pricing in.

Third, the analyst reaction was fast. Royal Bank of Canada set a $2.50 price target on AARD on October 23, according to MarketBeat's analyst data — a level that, after Friday's close at $1.39, still sits above the stock, but far below where shares traded only days earlier.

Key facts

Close: $1.39 on October 23, 2026, down $2.56, or 64.81%, from a $3.95 previous close.
Range: Opened at $2.99, high $3.00, low $1.39 — a new 52-week low. The prior 52-week range was $3.35 to $16.60.
Volume: About 16.11 million shares, versus 1.18 million on October 22.
The data: Exploratory results from the terminated Phase 3 HERO trial and open-label extension for ARD-101 in Prader-Willi syndrome; HERO randomized 67 of 90 planned participants before termination.
The catalyst sequence: FDA lifted the full clinical hold on ARD-101 on October 22; the exploratory data release followed at 7:00 a.m. ET on October 23, with a company webcast at 8:00 a.m. ET.
What's next on paper: A requested FDA meeting on a new Phase 3 design, with Prader-Willi clinical work expected to resume in 2027.

What's next

The next real milestones are procedural, not promotional: whether the FDA agrees to the meeting Aardvark wants, what design for a new Phase 3 trial comes out of it, and how the company funds a restart that is not expected until 2027. Until one of those lands, Friday's close is the market's verdict on the gap between a lifted hold and proven efficacy — and it was a harsh one. This post reports what happened and why markets reacted; it is not a recommendation to buy, sell, or hold any security.

Sources

FAQ

Why did Aardvark Therapeutics stock fall 65% on October 23, 2026?

AARD fell 64.81% to $1.39 after the company released exploratory data from its terminated Phase 3 HERO trial, in which only 67 of 90 planned patients were randomized and which its CEO said was not sufficient to draw definitive conclusions.

What is ARD-101?

ARD-101 is Aardvark's lead small-molecule drug candidate designed to suppress hunger, being developed for hyperphagia — constant, life-limiting hunger — in Prader-Willi syndrome, and for metabolic diseases.

Didn't the FDA just lift a hold on Aardvark's drug?

Yes. The FDA removed the full clinical hold on ARD-101 on October 22, 2026, which initially lifted the stock — before Friday's exploratory data release reversed the move.

What happens next for Aardvark?

The company plans to request an FDA meeting to align on a new Phase 3 trial design and expects to resume Prader-Willi clinical activities in 2027.